# Citrus Bergamot Supplement Insulin Sensitivity Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/citrus-bergamot-supplement-insulin-sensitivity-randomized-trial-evidence-review
Category: evidence-review
Summary: Citrus Bergamot Supplement Insulin Sensitivity Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available source
Last reviewed: 2026-08-17
Reviewed by: Migaku Evidence Review
# Citrus Bergamot Supplement Insulin Sensitivity Randomized Trial: What the Evidence Says

## Quick Answer

Citrus Bergamot Supplement Insulin Sensitivity Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection | narrative review | 3 | 2026-03-18 | 10.3390/nu18060955 |
| Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance | narrative review | 3 | 2025-09-05 | 10.3390/medsci13030180 |

## What The Sources Report

- Epidemiological studies indicate that CRS affects a substantial proportion of patients, with an estimated prevalence of up to 0.4% in the general population and 2-3% in individuals with diabetes and heart failure, and is associated with increased morbidity and mortality. [Carollo Caterina (2026); evidence level 3]
- Most preclinical studies investigating polyphenolic interventions have focused on type IV and type V CRS, particularly diabetes-induced chronic kidney disease with associated cardiovascular dysfunction. [Carollo Caterina (2026); evidence level 3]
- The downstream result is twofold: in skeletal muscle, glucose uptake is impaired; in the liver, glucose production remains inappropriately elevated. [Shimu Shakila Jahan (2025); evidence level 3]
- Although these conditions often coexist, emerging evidence suggests that hepatic inflammation and lipotoxicity, not simple steatosis, are the more potent drivers of metabolic impairment. [Shimu Shakila Jahan (2025); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For citrus bergamot supplement insulin sensitivity randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Carollo Caterina (2026). Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection. DOI: 10.3390/nu18060955. PMCID: PMC13028789. PMID: 41901130. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13028789/
- Shimu Shakila Jahan (2025). Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance. DOI: 10.3390/medsci13030180. PMCID: PMC12452514. PMID: 40981178. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12452514/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.